IFNA1 and neoplasm: To confirm this, we treated AE17 tumour-bearing mice 3 days after administration of ICB with antibodies against either IFNβ, IFNα (subtypes A, 1, 4, 5, 11, and 13) or their shared receptor IFNAR134.